Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Cyclophosphamide 909Carboplatin 786Paclitaxel 741pembrolizumab 741Bevacizumab 715Cisplatin 707Gemcitabine 621Docetaxel 583Rituximab 558Radiotherapy 546Dexamethasone 510Nivolumab 488Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 357Pemetrexed 336Oxaliplatin 335Cytarabine 334Lenalidomide 327Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 315Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 275

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × inavolisib × Clear all
NCT04191499 2026-03-17

INAVO120

Hoffmann-La Roche

Phase 2/3 Active not recruiting
325 enrolled 14 charts 1 FDA
Breast

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Hoosier Cancer Research Network

Phase 2 Terminated
52 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed
252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡